invest summari qualiti beat strong outlook
reiter overweight rate rais price target
increas price target driven upward earn revis think
core hold investor given durabl busi model
support posit macro outlook solid execut
posit quarter support thesi expect cash
flow strong give compani flexibl
prioriti capit alloc remain invest intern first
believ get greatest return busi develop
 return excess capit sharehold tax law chang
provid tailwind compani capit alloc goal
achiev oper revenu growth year industri
averag driven divers product portfolio
balanc perform across major intern market
grew adjust net incom faster sale oper
continu deliv long-term valu proposit grow revenu
line faster market grow net incom faster sale remain
commit valu proposit next five year anoth
year market growth companion anim busi especi
dermatolog expect sale apoquel cytopoint
outlook favor livestock especi
commit invest monoclon antibodi genet
diagnost vaccin new technolog
report ep factset consensu
higher estim present ep guidanc rang
factset consensu updat financi model
outlook increas ep estim
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
sever potenti risk posit invest thesi price target
restrict ban use antibacteri food-produc anim may
becom preval zoeti current sell antibacteri product govern
consum begun shift away consum prefer and/or govern
regul grow may affect zoetiss abil meet forecast
advers weather condit avail natur resourc could drive
price feed expens compon produc feed price rise
profit fall zoetiss custom may spend less anim health drug
lack new product launch and/or exist product fail gain market share
street good expect zoetiss new launch compani perform
in-lin better expect could downsid risk number
macro factor weather feed price currenc could advers impact sale
earn zoeti off-set sinc global busi said macro factor
global could pressur earn
oper margin expans lower expect zoeti still gross margin
expans expect compani meet target and/or margin
improv seen date sustain could downsid number
brand and/or gener competit key drug zoeti face competit could
headwind sale given larg number product portfolio compani
strong relationship custom see smaller type risk
bull bear base case analysi
use dcf multipl price-to-earnings analysi arriv bull bear case scenario
base analysi estim likelihood stock worth next
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casenew launch better expectedmargin improv better expectedmacro factor improvestrateg busi scenario casenew launch in-lin expectationsmargin improv in-lin expectationsmacro factor remain stableno busi scenario casenew launch expectationsmargin improv expectationsheadwind macro factor busi scenario exhibit varianc analysi
amount chang yoyamount chang increas sale dermatolog new product launch increas sale cattl poultri increas sale apoquel cattl latin swine product china new product launch simparica total gross oper oper non oper pre-tax tax net averag cantor fitzgerald research compani reportsactualcantor exhibit catalyst event calendar
datedriverupcom patent start expir sarolan label expans includ deer investor dayportfolio strategi swine vaccineapprov launchspr networkbuild new manufactur facil combin flea tick heartworm approv collabor licens agreement expir year ipo antiparasit process patent expir increas manufactur strategycomplet step two focus excel patent set patent set strategycomplet step three invest growthsourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
outlook us cost sale percentag sg interest expens tax rate adjust dilut net cantor fitzgerald research compani expect improv gross margin come expect pork return market growth expect reach peak sale dermatolog apoquel increment interest expens ad base higher debt balanc long-term natur new expect report dilut ep guidanc reflect foreign exchang rate earli expect companion continu grow faster livestock growth moder grow bigger base exhibit incom statement analysi
million except per share amount compound-annual-growth-rate year end decemb oper incom incom non-control incom attribut non-controlling net dilut changetot dilut cantor fitzgerald research compani revenu includ revenu full year impact fdah acquisit adjust net incom exclud purchas account adjust acquisit relat cost certain signific item organ sale growth revenu includ revenu kah acquisit adjust net incom exclud purchas account adjust acquisit relat cost certain signific item organ sale growth revenu includ extra month revenu kah acquisit adjust net incom exclud purchas account adjust acquisit relat cost certain signific item organ sale growth higher effect tax rate due non-recurr tax benefit exclud purchas account adjust restructur charg certain acquisition-rel cost certain signific exclud purchas account adjust acquisition-rel cost certain signific exclud restructur charg asset impair consult fee employe termin cost non recur cost becom stand-alone compani impair ipr asset commerci settlement reserv purchas account adjust acquisit integr relat cost relat tax effect exclud purchas account adjust transact cost integr cost oper effici initi suppli network strategi restructur charg cost-reduction/product initi asset impair stand-up cost foreign currenc loss relat venezuelan revalu relat tax exclud purchas account adjust transact cost integr cost restructur charg oper effici initi suppli network strategi restructur charg cost-reduction/product initi certain asset impair charg stand-up cost charg relat tax effect exhibit margin analysi
cantor fitzgerald research compani report exhibit quarterli sale analysi
million year end decemb new cantor fitzgerald research compani report exhibit annual sale analysi
new cantor fitzgerald research compani reportsyear end decemb exhibit analysi
million year end decemb flow provid oper activ net depreci includ cash separ intern cost net chang work net cash provid oper flow invest activitiespurchas net proce sale acquisit net cash other- net cash use invest flow financ activ repay issuanc long term dividend net cash use provid financ effect exchange-r cash net decreas increas cash equival begin equival end sourc cantor fitzgerald research compani report exhibit balanc sheet analysi
million year end decemb account receiv less allow doubt current defer tax assets- current total current plant properti identifi total total liabil sharehold equityaccount payabl accru total current long term debt total sharehold total stockhold non-controlling total liabil stockhold sourc cantor fitzgerald research compani report februari
zoeti anim health compani focus discoveri develop manufactur commerci anim health medicin
vaccin across livestock companion anim zoeti directli market product countri product sold
countri world-wide zoeti focuss eight core speci cattl swine poultri sheep fish form part compani
livestock segment dog cat hors manag compani companion anim segment zoetiss five major product
categori within segment anti-infect vaccin parasiticid medic feed addit pharmaceut
